M Ventures, Novartis Venture Fund and Pfizer Ventures are among the investors backing the DDR cancer therapeutics developer’s latest round, which took its total funding to $320m.

UK-based cancer therapy developer Artios Pharma secured $153m in a series C round on Tuesday from investors including pharmaceutical firms Merck Group, Novartis and Pfizer. Investment firms Omega Funds and TCG Crossover co-led the round, which included Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, Tetragon Financial Group, RTW Investments, Soleus Capital, Piper Heartland Healthcare…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.